Cranial Electrotherapy Arrives In New Zealand

Cranial Electrotherapy Arrives In New Zealand

Now available in New Zealand, Cranial Electrotherapy Stimulation (CES) is an electromedical treatment for anxiety, stress related illness, insomnia and chronic pain disorders including fibromyalgia.

North Shore’s John Hyde, promoter of CES therapy, believes this will become a first line treatment option, for these conditions as it is overseas. His brother, Australian psychiatrist Stephen Hyde, has incorporated it into his practice with significant success. This has led to him recently being interviewed, along with other fellow medical professionals and patients who use CES, by the Australian press and National television.

New Zealanders are catching on fast and local users have also had significant improvement from debilitating and distressing conditions such as panic attacks, insomnia, depression, bi-polar disorder and chronic pain.

Often from the first treatment people report feeling happier, more energetic and enthusiastic, their thinking is clearer, memory improves, they sleep better and feel generally calmer.

During CES treatment, a mild electrical stimulus is applied to the head with the use of electrodes that attach to the patient's ear lobes. This stimulates feel-good neurotransmitters and the alpha brain wave rhythm which reduces agitation and promotes a relaxed alertness.

An average length of treatment is generally 20-60 minutes daily for the first 1-3 weeks. Results are cumulative with people reporting needing the treatment less as they improve, unlike drug therapy where tolerance and dependence can be an issue. CES stimulates electrical and chemical changes that can led to a durable re-tuning back to normal function.

For the stressed or anxious patient other perks include no affect on weight or sex drive unlike some anti-depressant and anti-anxiety medications. In fact there are no significant side effects when using CES electrotherapy.

This technology was developed in the US by neurobiologist Dr Daniel Kirsch and has been used for over 27 years by GPs and mental health professionals in the US, Europe and more recently Australia, and now New Zealand.

The AlphaStim Medical Devices which provide CES were listed by MedSafe in December 2007. Further information about CES, medical devices, research studies, and uses, can be seen at www.medistim.co.nz

ENDS

http://www.medistim.co.nz

About Medistim New Zealand

Medistim New Zealand was founded to import and distribute Alpha-Stim medical devices in New Zealand and the South Pacific. It has been appointed the Authorised Distributor.

Alpha-Stim medical devices were listed by MedSafe in December 2007 for use in New Zealand. ARTG No 137247

The company is headquartered in Auckland, and staff have been trained in the use and support of the Alpha-Stim medical devices. These are already in use in some local medical institutions and homes in New Zealand.

© Scoop Media